Parkman Healthcare Partners LLC Sells 151,266 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Parkman Healthcare Partners LLC cut its stake in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 77.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,301 shares of the company's stock after selling 151,266 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 0.08% of Inari Medical worth $1,827,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Lighthouse Investment Partners LLC acquired a new position in Inari Medical during the second quarter worth $2,145,000. Aigen Investment Management LP acquired a new position in Inari Medical during the third quarter worth $428,000. Dynamic Technology Lab Private Ltd acquired a new position in Inari Medical during the third quarter worth $1,397,000. Integral Health Asset Management LLC increased its position in Inari Medical by 100.0% during the second quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company's stock worth $19,260,000 after buying an additional 200,000 shares during the last quarter. Finally, Vestal Point Capital LP increased its position in Inari Medical by 342.9% during the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock worth $63,922,000 after buying an additional 1,200,000 shares during the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Robert W. Baird upped their price target on shares of Inari Medical from $66.00 to $67.00 and gave the company an "outperform" rating in a report on Tuesday, October 29th. Needham & Company LLC reiterated a "hold" rating on shares of Inari Medical in a research note on Tuesday, October 29th. Truist Financial increased their target price on shares of Inari Medical from $46.00 to $50.00 and gave the stock a "hold" rating in a research note on Tuesday, October 29th. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research note on Friday, August 9th. They set a "buy" rating and a $68.00 price objective for the company. Finally, Piper Sandler upped their price target on shares of Inari Medical from $50.00 to $52.00 and gave the company a "neutral" rating in a report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Inari Medical presently has an average rating of "Hold" and an average price target of $58.89.

Inari Medical Stock Up 1.3 %

Shares of NARI stock traded up $0.65 on Wednesday, hitting $52.20. The stock had a trading volume of 562,889 shares, compared to its average volume of 976,121. The business has a 50 day moving average price of $46.67 and a 200 day moving average price of $47.62. The company has a market cap of $3.06 billion, a PE ratio of -38.18 and a beta of 0.97. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $67.13.

Insiders Place Their Bets

In other news, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares in the company, valued at approximately $22,265,500. This trade represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the transaction, the director now owns 601,233 shares in the company, valued at approximately $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 186,000 shares of company stock worth $8,990,990. 10.60% of the stock is owned by corporate insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.